Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...